(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/081840 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/519* (2006.01)
C07D 487/04 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2022/079324

(22) International Filing Date:
04 November 2022 (04.11.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/276,478	05 November 2021 (05.11.2021)	US
63/356,906	29 June 2022 (29.06.2022)	US
63/403,565	02 September 2022 (02.09.2022)	US

(71) Applicant: **FRONTIER MEDICINES CORPORATION** [US/US]; 151 Oyster Point Boulevard, Second Floor, South San Francisco, California 94080 (US).

(72) Inventors: **PATEL, Snahel**; c/o Frontier Medicines Corporation, 151 Oyster Point Boulevard, Second Floor, South San Francisco, California 94080 (US). **TANAKA, Hiroko**; c/o Frontier Medicines Corporation, 151 Oyster Point Boulevard, Second Floor, South San Francisco, California 94080 (US). **ERLANSON, Daniel A.**; c/o Frontier Medicines Corporation, 151 Oyster Point Boulevard, Second Floor, South San Francisco, California 94080 (US). **GERKEN, Philip A.**; c/o Frontier Medicines Corporation, 151 Oyster Point Boulevard, Second Floor, South San Francisco, California 94080 (US). **WIDEN, John C.**; c/o Frontier Medicines Corporation, 151 Oyster Point Boulevard, Second Floor, South San Francisco, California 94080 (US). **WILLIAMS, Monika Jane**; c/o Frontier Medicines Corporation, 151 Oyster Point Boulevard, Second Floor, South San Francisco, California 94080 (US). **DOTSENKO, Irina**; c/o Frontier Medicines Corporation, 151 Oyster Point Boulevard, Second Floor, South San Francisco, California 94080 (US).

(74) Agent: **DAVIES, Ioana** et al.; Goodwin Procter LLP, 100 Northern Avenue/IP Docketing 7th fl, Boston, Massachusetts 02210 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2023/081840 A1

(54) Title: KRAS G12C INHIBITORS

(57) Abstract: The present disclosure provides compounds and methods useful in the treatment and suppression of cancer, for example, useful for treating or suppressing cancers characterized by KRAS G12C. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.